Assertio (NASDAQ:ASRT) Releases Earnings Results

Assertio (NASDAQ:ASRT) announced its quarterly earnings data on Wednesday. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.06), Zacks reports. Assertio had a positive return on equity of 3.79% and a negative net margin of 54.46%. Assertio updated its FY 2025 guidance to EPS.

Assertio Price Performance

Assertio stock traded up $0.01 during mid-day trading on Wednesday, hitting $0.78. 278,982 shares of the company were exchanged, compared to its average volume of 379,384. Assertio has a 1-year low of $0.73 and a 1-year high of $1.80. The company has a quick ratio of 1.57, a current ratio of 2.01 and a debt-to-equity ratio of 0.30. The business has a fifty day moving average of $0.82 and a 200 day moving average of $0.97. The company has a market capitalization of $74.34 million, a PE ratio of -1.07, a price-to-earnings-growth ratio of 3.25 and a beta of 0.81.

Analyst Ratings Changes

A number of research firms have weighed in on ASRT. HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Assertio in a research note on Monday, December 16th. StockNews.com upgraded shares of Assertio from a “hold” rating to a “buy” rating in a research report on Wednesday, November 13th.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.